Progress and problems in the biology, diagnostics, and therapeutics of prion diseases. by Aguzzi, A et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.unizh.ch
Year: 2004
Progress and problems in the biology, diagnostics, and
therapeutics of prion diseases
Aguzzi, Adriano; Heikenwalder, Mathias; Miele, Gino
Aguzzi, Adriano; Heikenwalder, Mathias; Miele, Gino. Progress and problems in the biology, diagnostics, and
therapeutics of prion diseases. J. Clin. Invest. 2004, 114(2):153-60.
Postprint available at:
http://www.zora.unizh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.unizh.ch
Originally published at:
J. Clin. Invest. 2004, 114(2):153-60
Aguzzi, Adriano; Heikenwalder, Mathias; Miele, Gino. Progress and problems in the biology, diagnostics, and
therapeutics of prion diseases. J. Clin. Invest. 2004, 114(2):153-60.
Postprint available at:
http://www.zora.unizh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.unizh.ch
Originally published at:
J. Clin. Invest. 2004, 114(2):153-60
Progress and problems in the biology, diagnostics, and
therapeutics of prion diseases
Abstract
The term "prion" was introduced by Stanley Prusiner in 1982 to describe the atypical infectious agent
that causes transmissible spongiform encephalopathies, a group of infectious neurodegenerative diseases
that include scrapie in sheep, Creutzfeldt-Jakob disease in humans, chronic wasting disease in cervids,
and bovine spongiform encephalopathy in cattle. Over the past twenty years, the word "prion" has been
taken to signify various subtly different concepts. In this article, we refer to the prion as the
transmissible principle underlying prion diseases, without necessarily implying any specific biochemical
or structural identity. When Prusiner started his seminal work, the study of transmissible spongiform
encephalopathies was undertaken by only a handful of scientists. Since that time, the "mad cow" crisis
has put prion diseases on the agenda of both politicians and the media. Significant progress has been
made in prion disease research, and many aspects of prion pathogenesis are now understood. And yet
the diagnostic procedures available for prion diseases are not nearly as sensitive as they ought to be, and
no therapeutic intervention has been shown to reliably affect the course of the diseases. This article
reviews recent progress in the areas of pathogenesis of, diagnostics of, and therapy for prion diseases
and highlights some conspicuous problems that remain to be addressed in each of these fields.
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Progress and problems in the biology, 
diagnostics, and therapeutics of prion diseases
Adriano Aguzzi, Mathias Heikenwalder, and Gino Miele
Institute of Neuropathology, University Hospital Zurich, Zurich, Switzerland.
The term “prion” was introduced by Stanley Prusiner in 1982 to describe the atypical infec-
tious agent that causes transmissible spongiform encephalopathies, a group of infectious 
neurodegenerative diseases that include scrapie in sheep, Creutzfeldt-Jakob disease in humans, 
chronic wasting disease in cervids, and bovine spongiform encephalopathy in cattle. Over the 
past twenty years, the word “prion” has been taken to signify various subtly different concepts. 
In this article, we refer to the prion as the transmissible principle underlying prion diseases, with-
out necessarily implying any specific biochemical or structural identity. When Prusiner started 
his seminal work, the study of transmissible spongiform encephalopathies was undertaken by only a handful of 
scientists. Since that time, the “mad cow” crisis has put prion diseases on the agenda of both politicians and the 
media. Significant progress has been made in prion disease research, and many aspects of prion pathogenesis are 
now understood. And yet the diagnostic procedures available for prion diseases are not nearly as sensitive as they 
ought to be, and no therapeutic intervention has been shown to reliably affect the course of the diseases. This 
article reviews recent progress in the areas of pathogenesis of, diagnostics of, and therapy for prion diseases and 
highlights some conspicuous problems that remain to be addressed in each of these fields.
Prion pathogenesis, diagnostics, and therapy:  
where do we stand?
Prion diseases, also known as transmissible spongiform 
encephalopathies (TSEs), are invariably fatal neurodegenerative 
disorders affecting a broad spectrum of host species and arise via 
genetic, infectious, or sporadic mechanisms (Table 1). In humans, 
prion diseases result from infectious modes of transmission (vari-
ant Creutzfeldt-Jakob disease [vCJD], iatrogenic CJD, Kuru); 
inherited modes of transmission in which there is nonconservative 
germ line mutation of the PRNP gene open reading frame (famil-
ial CJD, Gerstmann-Sträussler-Scheinker Syndrome, Fatal Famil-
ial Insomnia) (1, 2); and modes of transmission that have as yet 
been neither determined nor understood (sporadic CJD [sCJD]). 
The clinical symptoms associated with each of the human prion 
disease forms vary dramatically (2).
Nomenclature applied to prion biology continues to be complex 
and confusing to nonspecialists. Here we utilize the term “prion” 
to denote the causative agent of prion diseases, without implying 
associated structural properties. We refer to the disease-associated 
prion protein (PrPSc), a disease-specific isoform of the host-encod-
ed cellular prion protein (PrPC), which accumulates in individu-
als affected with most forms of TSE (Figure 1) (3). While PrPSc is 
classically defined as partially protease-resistant, aggregated PrP, it 
has recently been shown that PrPC may undergo disease-associated 
structural modifications that do not impart properties of inherent 
protease resistance (4). In light of this, it is advisable that PrPSc be 
defined on the basis of disease-associated structural modifications 
rather than properties of protease resistance.
Prion diseases are conceptually recent; the first cases of 
Creutzfeldt-Jakob disease were described eight decades ago (5, 6), 
yet the protein-only theory of prion infection was originally for-
mulated in 1967 (7) and later refined and the term “prion” coined 
in 1982 (8). The precise physical nature of the prion agent is still 
the subject of intense scientific controversy. PrPSc may or may not 
be congruent with the infectious agent. It remains to be formally 
proven whether the infectious unit consists primarily or exclu-
sively of: (a) a subspecies of PrPSc; (b) an intermediate form of PrP 
(PrP*) (9); (c) other host-derived proteins (10); or (d) nonprotein 
compounds (which may include glycosaminoglycans and maybe 
even nucleic acids) (11). We still do not know, therefore, whether 
the prion hypothesis is correct in its entirety.
As with any other disease, a thorough mechanistic understand-
ing of pathogenesis is the best foundation for devising sensitive 
predictive diagnostics and efficacious therapeutic regimens.
The purpose of the present article is to discuss some aspects 
of the state of the art in prion science and their impact on prion 
diagnostics, primarily with respect to peripherally acquired prion 
disease. As of now, no causal therapies can be offered to prion dis-
ease victims. Yet we are witnessing the emergence of an impressive 
wealth of therapeutic approaches, some of which certainly deserve 
to be tested for their validity.
Progress in understanding prion pathogenesis
Prion pathogenesis is a dynamic process that can be broken down 
into spatially and temporally distinct phases: (a) infection and 
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peripheral replication; (b) transmigration from the periphery to the 
CNS (also termed “neuroinvasion”); and (c) neurodegeneration. 
But what are the mechanisms underlying neuroinvasion, and 
which cellular compartments are involved in replication and neu-
roinvasion of prions?
Peripheral replication
Cell tropism of prions varies dramatically among animal species 
and is also in part dependent on the particular strain of prion 
agent. For example, prions are lymphotropic in sheep scrapie 
and vCJD (12) but less so in sCJD (13) and bovine spongiform 
encephalopathy (BSE). Different prion strains can lead to differ-
ent routes of peripheral repli-
cation in experimental models 
of scrapie (14, 15), and, there-
fore, strain-encoded properties 
might also determine the route 
of peripheral replication. With 
respect to peripheral patho-
genesis of prion diseases, it is 
well established that replica-
tion of the prion agent occurs 
in high titers in lymphoid tis-
sues such as spleen and lymph 
nodes well before neuroinva-
sion and subsequent detection 
in the CNS (16).
Upon oral challenge, an 
early rise in prion infectiv-
ity is observed in the distal 
ileum of infected organisms. 
This applies to several spe-
cies but has been most exten-
sively investigated in sheep, 
and Western blot analyses and 
bioassays have shown that 
Peyer’s patches accumulate 
PrPSc and contain high titers 
of prion infectivity. This is 
true also in the mouse model 
of scrapie, where administra-
tion of mouse-adapted scrapie prions (Rocky Mountain Labora-
tory [RML] strain) induces a surge in intestinal prion infectivity 
as early as a few days after inoculation (17, 18). Indeed, immune 
cells are crucially involved in the process of neuroinvasion after 
oral application: mature follicular dendritic cells (FDCs), located 
in Peyer’s patches, may be critical for the transmission of scrapie 
from the gastrointestinal tract (16, 18).
Neuroinvasion
The resistance to prions of mice that lack expression of PrPC, 
encoded by Prnp (a single-copy gene located on chromosome 2 in 
mice and 20 in humans), is well documented (19, 20). While the 
Table 1
Spectrum of prion diseases of humans and animals
Prion disease Natural host species Etiology
sCJD Humans Unknown (somatic PRNP mutation?)
Familial Creutzfeldt-Jakob disease (fCJD) Humans Familial (germ line PRNP mutation)
Iatrogenic Creutzfeldt-Jakob disease (iCJD) Humans Surgical procedures (infection)
vCJD Humans Ingestion of BSE-contaminated food; transfusion medicine (infection)
Kuru Humans Ingestion, ritualistic cannibalism (infection)
Fatal Familial Insomnia (FFI) Humans Familial (germ line PRNP mutation)
Gerstmann-Sträussler-Scheinker Syndrome Humans Familial (germ line PRNP mutation)
Scrapie Sheep, goats Infection, natural; mode of transmission unclear
Chronic Wasting Disease (CWD) Deer, Elk Infection; mode of transmission unclear
BSE Cattle Ingestion of BSE-contaminated feed (infection)
Transmissible mink encephalopathy Mink Ingestion (infection); Origin unclear
Feline spongiform encephalopathy Cats Ingestion of BSE-contaminated feed (infection)
Spongiform encephalopathy of zoo animals Zoologic bovids, primates Ingestion of BSE-contaminated feed (infection)
 
Figure 1
Models of PrPC to PrPSc conversion. (A) The heterodimer model proposes that upon infection of an appro-
priate host cell, the incoming PrPSc (orange) starts a catalytic cascade using PrPC (blue) or a partially 
unfolded intermediate arising from stochastic fluctuations in PrPC conformations as a substrate, converting 
it by a conformational change into a new β-sheet–rich protein. The newly formed PrPSc (green-orange) will 
in turn convert new PrPC molecules. (B) The noncatalytic nucleated polymerization model proposes that 
the conformational change of PrPC into PrPSc is thermodynamically controlled: the conversion of PrPC to 
PrPSc is a reversible process but at equilibrium strongly favors the conformation of PrPC. Converted PrPSc is 
established only when it adds onto a fibril-like seed or aggregate of PrPSc. Once a seed is present, further 
monomer addition is accelerated.
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precise physiological function of PrPC is unclear, expression of it 
is absolutely required for transportation of the infectious agent 
both from the peripheral sites to the CNS (21) and within the CNS 
(22). However, reconstitution of Prnp knockout (Prnpo/o) mice with 
WT bone marrow is insufficient to restore neuroinvasion in Prnpo/o 
mice (21). Hence one could argue that the elemental compartment 
required for prion neuroinvasion is stromal and must express 
PrPC. Nevertheless, in adoptive transfer experiments on Prnpo/o 
mice with WT bone marrow, the capability of the spleen to accu-
mulate prions of the RML strain is restored (21, 23). This suggests 
that hematopoietic cells transport prions from the entry site to the 
lymphoreticular system (LRS), which accumulates and replicates 
prions. B lymphocytes (not necessarily expressing PrPC) are crucial 
for peripheral prion spread and neuroinvasion (24–26).
This dependence of FDCs on lymphotoxin (LT) signaling by B 
cells likely may explain — at least in part — the apparent requirement 
for B cells in peripheral pathogenesis: FDCs have been reported to 
accumulate PrPSc following scrapie infection (27). Indeed, blockade 
of LT signaling via administration of a soluble, dimeric LTβ recep-
tor immunoglobulin fusion protein (LTβR-Ig) ablates mature FDCs 
and significantly impairs peripheral prion pathogenesis (28, 29).
FDCs are bifunctional cells: they support the formation and 
maintenance of the lymphoid microarchitecture but also play a 
role in antigen trapping — capturing immune complexes by Fcγ 
receptors and binding opsonized antigens to the CD21/CD35 
complement receptors. Two studies have demonstrated that the 
complement system is relevant to prion pathogenesis. Mice geneti-
cally engineered to lack complement factors (30) or mice depleted 
of the C3 complement component (31) exhibited enhanced resis-
tance to peripheral prion inoculation. However, FDCs are most 
likely immobile cells and therefore unlikely to be responsible for 
prion transport into the CNS.
But just which cell types are involved in neuroinvasion? The 
innervation pattern of lymphoid organs is primarily sympathetic 
(32). Sympathectomy delays the onset of scrapie, while sympa-
thetic hyperinnervation enhances splenic prion replication and 
neuroinvasion, which suggests that innervation of secondary lym-
phoid organs is the rate-limiting step to neuroinvasion (33). How-
ever, there is no physical synapse between FDCs and sympathetic 
nerve endings (34). So how can prions transmigrate from FDCs to 
sympathetic nerve fibers? A series of recent experiments (discussed 
below) may go some way toward providing answers.
FDC positioning is a primary determinant  
of velocity of neuroinvasion
We investigated how the distance between FDCs and splenic nerves 
affects the velocity of neuroinvasion, utilizing mice deficient in the 
CXC chemokine receptor 5 (CXCR5), which directs lymphocytes 
toward specific microcompartments (35). While density, distri-
bution, and branching patterns of sympathetic nerve processes 
in CXCR5–/– spleens are normal, the distance between FDCs and 
nerve endings is greatly reduced (36).
After peripheral administration of high doses of prions, velocity 
of pathogenesis was similar in CXCR5–/– and WT mice; however, 
delivery of smaller inocula resulted in a dose-dependent increase in 
incubation periods in WT mice that was not evident in CXCR5–/– 
mice. Peripheral prion pathogenesis in CXCR5–/– mice is therefore 
more efficient upon incremental reduction of the inoculum.
What is the basis of this reduced incubation period? Kinetics 
measurements of prion infectivity titers in the thoracic spinal cord 
provided the answer: following peripheral administration, only 
traces of infectivity were found in WT spinal cords at 80 days post-
inoculation (dpi), whereas infectivity rose to measurable levels in 
the spinal cords of CXCR5–/– mice already at 60 dpi. This suggests 
that increased velocity of prion entry into the CNS in CXCR5–/– 
mice is due to the repositioning of FDCs near highly innervated, 
splenic arterioles (Figure 2). This was validated by the finding that 
incubation periods were prolonged in CXCR5–/– mice treated with 
soluble LTβR-Ig to deplete mature FDCs.
Hence topographical relationships within lymphoid organs con-
tribute to prion neuroinvasion. However, it remains to be deter-
mined whether this results from passive diffusion of prions or 
whether mobile cells (e.g., germinal center B cells) are involved in 
an active transport process.
This study also raises the possibility that spread of infection 
to peripheral nerves occurs more rapidly when FDCs are in close 
proximity to nerves in lymphoid tissue other than spleen, such 
as Peyer’s patches. Indeed, FDCs are crucial to disease progres-
sion but only during a short window of time following oral 
scrapie challenge (17). This implicates the efficiency of neuroim-
mune transfer of prions as a primary determinant of neuroinva-
sion. The detection of PrPSc in spleens of sCJD patients (12) sug-
gests that the interface between cells of the immune system and 
Figure 2
Positioning of FDCs in spleens of WT and CXCR5–/– mice. (A and B) 
Diagrammatic representation of white pulp follicles in prion-infected 
CXCR5–/– and WT mice. Anti-CD21 immunostaining was performed to 
visualize the lymphoid white pulp follicle microarchitecture. (C) Atypical-
ly localized perivascular FDCs in lymph follicles in CXCR5–/– mice. Sym-
pathetic nerves, visualized with antibodies to tyrosine hydroxylase (TH), 
are in close vicinity to FDCs (visualized by FDC-M1 immunostaining) 
(D). Scale bar: 50 mm. In contrast, sympathetic nerves in WT FDCs 
are localized in B cell areas at the periphery of the follicles (E and F). 
Arrowheads indicate TH and FDC-M1 positive areas. (G) Sympathetic 
nerves lining the thoracic spinal cord connect lymphoid organs and the 
CNS. (H) Shortened prion disease incubation period in CXCR5–/– mice 
inoculated intraperitoneally, relative to WT controls.
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peripheral nerves (the neuroimmune connection) might also be 
of relevance in sporadic prion disease.
The neurodegeneration issue
There has certainly been progress in understanding the events 
underlying peripheral prion pathogenesis and neuroinvasion (37). 
However, prions exert their destructive effects exclusively within 
the CNS. The precise cause of neurodegeneration remains poorly 
understood and is a point of contention among prionologists. It 
seems unlikely that PrPSc is directly toxic, since tissue devoid of 
PrPC that subsequently accumulates PrPSc remains healthy and 
free of pathology (20, 38). During the conversion process, PrPC lev-
els may be depleted, yet this is also an unlikely cause of pathology, 
since ablation of PrPC does not result in scrapie-like symptoms 
(39), even when ablated postnatally (40).
Lindquist and colleagues have suggested a mechanism that 
may account for prion-associated toxicity: (a) expression of a 
PrP variant resident in the cytosol was strongly neurotoxic in 
cultured cells and transgenic mice, which suggests a common 
framework for diverse PrP neurodegenerative disorders (41); 
and (b) PrP, retrogradely transported out of the endoplasmic 
reticulum, produced amorphous aggregates of PrP possess-
ing partial proteinase K resistance in the cytosol. Once conver-
sion occurred, it was self-sustaining (42). It will be interesting 
to determine whether the disease generated in these mice is, in 
some way, transmissible. However, while the results obtained 
here are certainly intriguing, it should be noted that reports else-
where, although not refuting these observations, argue against 
the contribution of such potential neurotoxic PrP species (43, 
44). Similarly, it has been reported that PrPC in some forms of 
prion disease assumes a transmembrane topology, C-terminal 
transmembrane PrP (CtmPrP), and that the extent of neurotoxicity 
is a result of concentration of CtmPrP, thereby arguing that 
CtmPrP may represent a major toxic moiety (45, 46). However, 
while we still do not understand the biochemical events involved 
in cytosolic or CtmPrP-induced neurotoxicity, elucidation of this 
may aid in the much-needed identification of therapeutic tar-
gets. Additionally, in-depth characterization of transgenic mice 
expressing amino-terminally truncated PrPC (47), in which cere-
bellar neurodegeneration occurs, may not only aid in the elucida-
tion of the molecular events responsible for potentially common 
neurodegenerative processes but perhaps also provide clues to 
the physiological function of PrPC itself.
Prion diagnostics
The ability to secure early diagnosis is vital for therapeutic inter-
ventions to be of real value. With respect to animals destined for 
the human food chain, there is the additional demand to deter-
mine presence of the prion agent in tissues in asymptomatic 
organisms, well before the appearance of any clinical symptoms. 
This applies equally to the detection of prions in humans, who 
may participate in tissue donation programs.
Prions were transmitted via blood transfusion in sheep using 
blood obtained from infected animals prior to the onset of clinical 
symptoms (48, 49). If the same route applies to humans, this could 
represent a nightmare scenario for the blood transfusion services 
(50). A transfusion recipient received blood from an individual 
harboring the vCJD agent 3.5 years prior to the development of 
Table 2
Molecular diagnosis of prion disease and prion infectivity
 Method Diagnostic principle Platform Properties
Disease-associated PrP Prionics–Check, Western blot PrPSc Western blot Very high specificity,  
    medium throughput
 Prionics–Check LIA PrPSc ELISA High throughput
 Bio-Rad ELISA PrPSc ELISA High throughput
 Enfer Scientific TSE kit PrPSc ELISA High throughput
 InPro Biotechnology PrPSc and protease-sensitive ELISA High throughput
 CDI PrPSc
 Anti-YYR motif mAb’s PrPSc Immunoprecipitation May obviate proteolytic digest
Genetic tests  PRNP ORF mutation DNA sequencing Unambiguous diagnosis  
    of predisposition
Surrogate markers  14-3-3 Western blot, ELISA Positive in cerebrospinal fluid
  Blood EDRF levels Northern blot, RT-PCR Extraneural diagnostics
Prion infectivity assays Endpoint bioassay Prion infectivity Transmission to mice Highly sensitive and  
    precise, long incubation  
    times, extremely costly
 Bioassay by incubation time Prion infectivity Transmission to mice High sensitivity,  
    imprecise, very costly
 Scrapie cell assay Prion infectivity Transmission to cells High sensitivity,  
    currently medium throughput,  
    only available for mouse prions
 Scrapie cell assay  Prion infectivity Transmission to cells High sensitivity and  
 in endpoint format (SCEPA)   precision, low throughput
All currently reported methods of assessing the presence of prion disease are listed, including validated methods and nonvalidated experimental approach-
es. Most commercial assays rely on the direct detection of disease-associated PrPSc. LIA, luminescence immunoassay; CDI, conformation-dependent 
immunoassay. ORF, open reading frame. 
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any clinical signs of prion disease in the donor. The unfortunate 
recipient developed disease 6.5 years after the transfusion.
Detection of PrPSc
To be truly useful, prion diagnostics should identify “suspect” cases 
as early during pathogenesis as possible. However, the currently 
available methods are quite insensitive when compared with those 
available for other infectious diseases. PrPSc represents the only dis-
ease-specific macromolecule identified to date, and all approved 
commercial testing procedures are based on the immunological 
detection of PrPSc. While around 50 companies are reported to be 
developing prion diagnostic assays, all commercial test kits vali-
dated for use by the European Union rely on proteolytic removal of 
endogenous PrPC prior to detection of PrPSc (Table 2). In addition, 
the conformation-dependent immunoassay (4) utilizes the differ-
ential binding of antibodies to native or denatured PrPSc.
Circumvention of the protease digestion step might theoreti-
cally yield increased sensitivity of PrPSc-based detection methods 
and make these methods more amenable to high-throughput 
technologies. However, it has proved difficult to discriminate 
between PrPC and PrPSc with antibodies, despite some early reports 
(51). Interestingly, tyrosine-tyrosine-arginine (YYR) motifs (52) 
were reasoned to be more solvent-accessible in the pathological 
isoform of PrP, and a monoclonal antibody directed against these 
motifs was reported to be capable of selectively detecting PrPSc 
across a variety of platforms. However, YYR motifs are certainly 
not unique to pathological prion proteins, and it remains to be 
determined whether this reagent can really improve the sensitivity 
of detection of prion infections.
Deposition of PrPSc in lymphoid tissues of human prion disease 
patients has long been believed to be restricted to vCJD. However, 
recent results (12) imply that PrPSc is present in spleens and muscle 
tissue from as much as one third of patients with sCJD. It is pres-
ently unclear whether the patients with extraneural PrP represent a 
specific subset of CJD patients or whether the extraneural-negative 
patients may simply deposit PrPSc in muscle and spleen at levels 
that are below the detectability threshold of the assay. If the lat-
ter scenario proves true, and if the assay sensitivity can be raised, 
minimally invasive muscle biopsies may replace brain biopsy in 
clinical CJD diagnostics.
Surrogate markers and prion infectivity
While presence of PrPSc secures diagnostic association with the 
presence of prion disease, PrPSc is not always easily detectable in 
several forms of prion disease (53–55). In order to enhance the safe-
ty of the blood supply and of products of bovine origin, absolute 
specificity in securing diagnosis of asymptomatic prion disease 
may not be required. Instead, it may be prudent to accommodate 
less than 100% specificity with a panel of surrogate markers capa-
ble of identifying donated blood units from “suspect” individuals 
rather than requiring definitive diagnosis. It could be envisaged 
that wide-scale primary screens accommodate a certain degree of 
loss of specificity to identify samples to be re-tested in a secondary 
screen utilizing more specific (and likely labor-intensive) criteria.
Several research efforts have been directed at identifying tran-
scripts and proteins differentially expressed in tissues of prion-
infected animals relative to disease-free controls (56–58). However, 
these have mostly focused primarily either on prion-infected neural 
cell lines or on CNS tissue, frequently with emphasis on late-stage 
disease. Ideally, these surrogate markers should be detectable (and 
differentially expressed) in easily accessible body fluids, such as 
blood or urine. At present, only one extraneural gene was reported 
to be differentially expressed during prion infection (59): erythroid 
differentiation–related factor (EDRF; also known as erythroid-
associated factor) levels were progressively reduced in spleens of 
prion-infected mice throughout pathogenesis and also in blood 
of experimentally infected mice, cattle with BSE, and sheep with 
clinically manifest scrapie.
Assessment of the levels of surrogate markers in healthy indi-
viduals is crucial in order to define the normal range of expression 
(according to age, sex, etc.) in order to determine what represents 
abnormal levels. In this respect, it is worth noting that determina-
tion of normal expression range must utilize appropriate controls. 
For example, EDRF transcript levels have recently been reported 
to show a broad range of variation in healthy human subjects (60). 
However, since EDRF is an erythroid-specific transcript, it would 
be imperative to utilize other erythroid transcripts as internal con-
trols to normalize for variations in numbers of circulating cells in 
which the transcript under study is expressed relative to total cells. 
More searches for surrogate markers would certainly be useful, and 
it is likely that surrogate markers of prion disease, particularly if 
they are detectable in body fluids, will expand the panel of tools 
available for screening for prion infections.
It is also worth noting here that recent advances in neuroimaging 
techniques, particularly with respect to MRI, may lead to clinically 
useful methods of assessment of prion disease in humans, perhaps 
even the ability to distinguish between sCJD and vCJD (61). For 
example, in vCJD the pulvinar sign (a high T2 MRI signal in the 
posterior thalamus) has been suggested to be relatively specific for 
vCJD, being present in approximately 75% of vCJD patients tested 
(62). In sCJD, fluid-attenuated inversion recovery and diffusion-
weighted MRI sequences appear to be associated with high sensi-
tivity and specificity. MRI imaging techniques such as these may 
therefore represent a relatively noninvasive method to corroborate 
suspicion of clinical presentation of human prion disease.
While surrogate markers such as S-100, neuron-specific enolase, 
and 14-3-3 protein have been suggested as potential biomarkers 
of prion disease using body fluids such as cerebrospinal fluid 
(CSF) (63, 64), it is worth remembering that these are clearly sur-
rogate markers of general neurodegenerative disease and are not 
therefore predictive for human prion disease. For example, one 
study reported false positives of 14-3-3 detection in CSF samples 
of patients with herpes simplex encephalitis, hypoxic brain dam-
age, atypical encephalitis, intracerebral metastases of a bronchial 
carcinoma, and metabolic encephalopathy (65).
It should not be forgotten that there is no ultimate consen-
sus on the nature of the prion: PrPSc itself might represent a sur-
rogate marker of prion disease (66). The real gold standard of 
prion diagnostics is the detection of prion infectivity (whether 
or not PrPSc is present). Until recently, the only method available 
to assay for prion infectivity was the use of the mouse bioassay, 
in which serial dilutions of test material are inoculated into mice 
and onset of disease noted. However, this procedure suffers from 
inaccuracy and is limited by the requirements for scores of mice 
and significant lengths of time. Recently, the use of highly sus-
ceptible cloned neural cell lines has provided what appears to be 
an assay that delivers a substantial reduction in both cost and 
time required to perform prion bioassays and may lend itself 
to high-throughput automation (67). Such assays may advance 
methodologies aimed at diagnostic assessment of the presence of 
science in medicine
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the prion agent. However, it should be noted that these cell lines 
are currently reported only to be permissive to murine prions. It 
is to be expected that the spectrum of prion strains that can be 
assayed using this technology will expand.
Prion therapy
For all the promising approaches that are being explored (Table 3), 
no therapy for prion diseases is available as of yet. Many substances 
appear to possess prion-curing properties in vitro, including Congo 
red (68), amphotericin B, anthracyclines (69), sulfated polyanions 
(70), porphyrins (71), branched polyamines (72), �-sheet breakers 
(73), the spice curcumin (74), and recently even small interfering 
RNAs (75). The majority of these molecules exert their biological 
effects by directly or indirectly interfering with conversion of PrPC to 
PrPSc, thereby also aiding clearance of PrPSc. Yet none of these com-
pounds have proved very effective for actual therapy.
In a recent report, results obtained in mice have led to the theory 
that administration of cytidyl-guanyl oligodeoxynucleotides (CpG-
ODNs), which stimulate the innate immune system via toll-like 
receptor 9 (TLR9) signaling receptors on a variety of immune cells, 
may represent an applicable treatment regimen to delay prion dis-
ease in humans (76). Here it was shown that the incubation period 
of prion disease was extended in mice multidose treated with CpG-
ODNs for twenty days. It was concluded that stimulation of innate 
immunity accounts for this apparent anti-prion effect, possibly 
through induction of anti-PrP antibodies. However, this is diffi-
cult to reconcile with several studies indicating that immune defi-
ciencies of various sorts inhibit prion pathogenesis (24, 25, 30, 77). 
In addition, prion pathogenesis is unhampered in MyD88–/– mice, 
in which there is impaired TLR9 signaling (78). In fact, repeated 
CpG-ODN treatment has severe side effects, ranging from lym-
phoid follicle destruction and impaired antibody class switch to 
the development of ascites, hepatotoxicity, and thrombocytopenia 
(79). In addition, anti-PrP antibodies are not detectable in CpG-
ODN–treated mice (79). It is likely therefore that the anti-prion 
effects of repeated CpG-ODN treatment arise via indiscriminate 
and undesirable follicular destruction.
Is vaccination against prion disease possible?
Anti-PrP antibodies (30) and F(ab) fragments to PrP (80, 81) can 
suppress prion replication in cultured cells. However, the mamma-
lian immune system is essentially tolerant to PrPC (82). Ablation 
of Prnp (39) renders mice highly susceptible to immunization with 
prions (22). Tolerance can be circumvented by transgenic expres-
sion of an immunoglobulin µ chain containing the epitope-inter-
acting region of a high-affinity anti-PrP monoclonal antibody. 
This sufficed to block prion pathogenesis upon intraperitoneal 
prion inoculation (83). Passive immunization may be a useful 
strategy for prophylaxis of prion diseases, since it has been shown 
that passive transfer of anti-PrP monoclonal antibodies prior to 
the onset of clinical symptoms is able to delay the onset of prion 
disease in mice inoculated intraperitoneally (84). Unfortunately, 
several efforts aimed at active immunization strategies have met 
with little success due to the robust immune tolerance to PrPC. In 
this respect, it is certainly worth noting that extensive neuronal 
apoptosis in hippocampus and cerebellum has been shown follow-
ing intracranial delivery of monoclonal antibodies reactive against 
a subset of PrP epitopes (85). The implications here are obvious; 
clearly, exhaustive in-vivo safety trials must be performed prior to 
the utilization of such strategies in humans.
Soluble prionostatic candidates
Do any serious candidates for prion therapeutic strategies exist? It 
is well established that expression of two PrPC moieties that differ 
subtly from each other are able to inhibit prion replication (10). 
For example, humans heterozygous for a common PRNP polymor-
phism at codon 129 are largely protected from CJD (86). Although 
the precise molecular basis for this effect is unclear, it is possible 
that heterologous PrPC may exert inhibitory action on prion rep-
lication by sequestration. This has been addressed directly by 
fusion of PrPC to an immunoglobulin Fcγ domain (87), allowing 
for ligand dimerization, expression of the molecule as a soluble 
moiety, and also, therefore, increased overall stability in body flu-
ids. Transgenetic expression of this PrP-Fc2 fusion protein resulted 
in significant prolongation of incubation period upon prion inoc-
Table 3
Approaches to prion therapy
Therapeutic approach Target Properties References
Polyanions Possibly membrane-resident PrPSc Efficient in cultured cells;  (70, 88) 
  relatively toxic in vivo
Curcumin Unknown Efficacy in vivo unproven (74)
Soluble lymphotoxin receptor FDCs Effective in vivo, but only on peripheral  (28, 29) 
  pathogenesis; moderate untoward effects
CpG oligodeoxynucleotides FDCs, DCs; B cells and macrophages Severely immunoclastic at doses effective in vivo (76, 79)
Anti-PrP antibodies PrPC Effective in vivo only if administered in massive doses (80, 83, 84)
Amyloidotropic intercalators  PrPSc Toxic; questionable efficacy in vivo (89, 90) 
 (e.g., Congo red)
Chemical or immunological  Peripheral nerves involved  Very efficacious, but unacceptable  (33) 
 sympathectomy in neuroinvasion toxicity in vivo
Polyene antibiotics Possibly membrane-resident PrPSc Low efficacy in vivo (91, 92)
Chlorpromazine and quinacrine Unknown Questionable efficacy in vivo; hepatotoxicity (93–95)
Soluble dimeric PrPC  PrPSc Effective as transgene, but efficacy  (87) 
 immunoadhesin  upon injection unproven
While most substances investigated so far may possess prion-curing potential in vitro, no effective therapeutic substance has been identified so far for 
actual in-vivo therapy in humans. However, fusion proteins either antagonizing soluble prion protein or depleting mature FDCs have been shown to effi-
ciently prolong the incubation time of infected animals.
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ulation via competition with PrPSc. It remains to be established 
whether PrP-Fc2 is acting as an anti-prion compound when deliv-
ered exogenously. If so, soluble prion protein mutants may well 
represent anti-prion compounds.
An outlook for prion therapy
Prion diseases continue to present a diagnostic and therapeu-
tic challenge to clinicians and researchers worldwide. There are 
many aspects of prion biology that remain unclear; we still do 
not know the precise physical nature of the infectious agent, the 
molecular and biochemical mechanisms underlying associated 
neurodegeneration, or the physiological function of PrPC. The 
diagnostic tools currently available for prion diseases are signifi-
cantly less sensitive and satisfactory than those available for other 
infectious diseases. Additionally, there is a dearth of therapeutic 
intervention strategies available for these diseases. However, that 
said, the last decade or so of prion research has witnessed astound-
ing advances in our knowledge and understanding of basic prion 
biology, and the field has attracted increasing numbers of research-
ers from diverse disciplines. Undoubtedly, this trend will trigger 
further important advances in prion science.
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